Company news

Heron Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Recent Corporate Updates

May 9, 2021

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Recent Corporate Updates

February 23, 2021

Heron Therapeutics to Present at Several Upcoming Virtual Investor Conferences

February 16, 2021

Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery

January 20, 2021

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

January 10, 2021

Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain

November 12, 2020

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Highlights Recent Corporate Updates

November 4, 2020

Heron Therapeutics Receives European Commission Authorization for ZYNRELEF™ (HTX-011) for the Treatment of Postoperative Pain

September 27, 2020

Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

September 15, 2020

Heron Therapeutics to Present at Cantor Virtual Global Healthcare Conference

September 10, 2020

Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain

September 7, 2020

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020 and Highlights Recent Corporate Updates

August 4, 2020

Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain

July 23, 2020

Heron Therapeutics Announces Initiation of Phase 2 Clinical Study of CINVANTI® for the Treatment of COVID-19

July 15, 2020

Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain

June 28, 2020

Heron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty

June 3, 2020

Heron Therapeutics Announces Initiation of Phase 1b/2 Clinical Study of HTX-034 for the Treatment of Postoperative Pain

May 17, 2020

Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2020 and Highlights Recent Corporate Updates

May 5, 2020

Heron Therapeutics to Present at the 19th Annual Needham Virtual Healthcare Conference

April 8, 2020

Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019 and Highlights Recent Corporate Updates

March 1, 2020

Heron Therapeutics to Present at the 40th Annual Cowen Healthcare Conference

February 24, 2020

Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain

February 18, 2020

Heron Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

February 17, 2020

Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises

January 12, 2020

Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain

December 15, 2019

Health Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain

December 2, 2019

Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference

November 25, 2019

Heron Therapeutics to Present at the Jefferies London Healthcare Conference

November 13, 2019

Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference

November 12, 2019

Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates

November 11, 2019

Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain

October 27, 2019

Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC)

October 21, 2019

Heron Therapeutics Announces Proposed Public Offering of Common Stock

October 2, 2019

Heron Therapeutics Announces Pricing of Public Offering of Common Stock

October 2, 2019

Heron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty

October 1, 2019

Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain

September 30, 2019

Heron Therapeutics Appoints Stephen Davis to Board of Directors

September 30, 2019

Heron Therapeutics Appoints Kimberly Manhard to Board of Directors

September 30, 2019

Heron Therapeutics Announces Publication of Results from EPOCH 2, a Phase 3 Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

August 19, 2019

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Updates

August 4, 2019

Heron Therapeutics to Present at 2019 JMP Securities Life Sciences Conference

June 12, 2019

Heron Therapeutics to Present at Jefferies 2019 Healthcare Conference

May 28, 2019

Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain

April 30, 2019

Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management

March 31, 2019

← Newer news releases

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 42 decks. Every deck is listed under its year.